omniture

Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry

2008-07-14 11:42 4655

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech as Vice President of Medicinal Chemistry.

(Logo: http://www.prnasia.com/sa/200708281726.jpg )

As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientific experience and proven leadership capability to his new role in WuXi. Prior to joining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego based biotechnology company, as Vice President of Research and Development and Chief Scientific Officer from March 2003 to March 2008. Before joining TargeGen, Dr. Soll held senior positions with increasing responsibilities at Ontogen Corporation and 3-Dimensional Pharmaceutical, Inc.

Dr. Soll is well recognized and respected for his scientific acuity from the academic and industry circles. Amongst his most recent achievements are first-in-class drug development nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders.

As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services platform. Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very excited to welcome Dr. Soll on board to lead and expand our already strong medicinal chemistry unit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi, Rich has a unique perspective on how to maximize service value creation for clients. His broad experience in the pharmaceutical industry and proven track record as a leader make him an ideal fit for the organization. I am confident that under his leadership our medicinal chemistry service capability will be stronger and further integrated with those of other services."

Dr. Soll received his B.S. in Chemistry from the University of Massachusetts, Massachusetts and his Ph.D. in Chemistry from Dartmouth College, New Hampshire. He was also a chemistry post-doctoral fellow at Harvard University with Professor E. J. Corey.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

Source: WuXi PharmaTech (Cayman) Inc.
Related Stocks:
NYSE:WX
collection